WVE vs. LNTH, PCVX, MTSR, CYTK, MRUS, AKRO, KRYS, RNA, SRRK, and ADMA
Should you be buying WAVE Life Sciences stock or one of its competitors? The main competitors of WAVE Life Sciences include Lantheus (LNTH), Vaxcyte (PCVX), Metsera (MTSR), Cytokinetics (CYTK), Merus (MRUS), Akero Therapeutics (AKRO), Krystal Biotech (KRYS), Avidity Biosciences (RNA), Scholar Rock (SRRK), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.
WAVE Life Sciences vs. Its Competitors
WAVE Life Sciences (NASDAQ:WVE) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.
WAVE Life Sciences currently has a consensus price target of $20.15, indicating a potential upside of 139.93%. Lantheus has a consensus price target of $131.20, indicating a potential upside of 79.90%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Lantheus.
Lantheus has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
WAVE Life Sciences has a beta of -1.01, indicating that its share price is 201% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500.
Lantheus has a net margin of 16.55% compared to WAVE Life Sciences' net margin of 0.00%. Lantheus' return on equity of 36.99% beat WAVE Life Sciences' return on equity.
89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 24.0% of WAVE Life Sciences shares are held by insiders. Comparatively, 1.5% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Lantheus had 8 more articles in the media than WAVE Life Sciences. MarketBeat recorded 14 mentions for Lantheus and 6 mentions for WAVE Life Sciences. Lantheus' average media sentiment score of 1.22 beat WAVE Life Sciences' score of 1.15 indicating that Lantheus is being referred to more favorably in the news media.
Summary
Lantheus beats WAVE Life Sciences on 11 of the 16 factors compared between the two stocks.
Get WAVE Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
WAVE Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:WVE) was last updated on 7/25/2025 by MarketBeat.com Staff
Free WVE Stock Alerts